Bifogade filer
PDF
Kurs & Likviditet
-2,10%
|
0,10 MSEK
Kursutveckling och likviditet under dagen för detta pressmeddelande
Kalender
| 2024-02-29 | Bokslutskommuniké 2023 |
| 2023-11-23 | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | Kvartalsrapport 2023-Q2 |
| 2023-06-30 | Årsstämma 2023 |
| 2023-05-31 | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | Ordinarie utdelning RLS 0.00 SEK |
| 2023-02-28 | Bokslutskommuniké 2022 |
| 2023-02-09 | Extra Bolagsstämma 2022 |
| 2022-11-24 | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | Ordinarie utdelning RLS 0.00 SEK |
| 2022-05-19 | Årsstämma 2022 |
| 2022-05-11 | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | Bokslutskommuniké 2021 |
| 2021-11-12 | Kvartalsrapport 2021-Q3 |
| 2021-07-16 | Kvartalsrapport 2021-Q2 |
| 2021-06-17 | Årsstämma 2021 |
| 2021-05-27 | Ordinarie utdelning RLS 0.00 SEK |
| 2021-05-07 | Kvartalsrapport 2021-Q1 |
| 2021-02-10 | Bokslutskommuniké 2020 |
| 2020-11-12 | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | Ordinarie utdelning RLS 0.00 SEK |
| 2020-05-26 | Årsstämma 2020 |
| 2020-05-15 | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | Bokslutskommuniké 2019 |
| 2019-11-15 | Kvartalsrapport 2019-Q3 |
| 2019-08-19 | Extra Bolagsstämma 2019 |
| 2019-08-15 | Kvartalsrapport 2019-Q2 |
| 2019-05-31 | Ordinarie utdelning RLS 0.00 SEK |
| 2019-05-29 | Årsstämma 2019 |
| 2019-05-15 | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | Bokslutskommuniké 2018 |
| 2018-11-30 | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | Kvartalsrapport 2018-Q2 |
| 2018-06-14 | Ordinarie utdelning RLS 0.00 SEK |
| 2018-06-13 | Årsstämma 2018 |
| 2018-05-31 | Kvartalsrapport 2018-Q1 |
| 2018-02-28 | Bokslutskommuniké 2017 |
| 2017-11-28 | Kvartalsrapport 2017-Q3 |
| 2017-11-15 | Extra Bolagsstämma 2017 |
| 2017-08-31 | Kvartalsrapport 2017-Q2 |
| 2017-06-09 | Ordinarie utdelning RLS 0.00 SEK |
| 2017-06-08 | Årsstämma 2017 |
| 2017-05-31 | Kvartalsrapport 2017-Q1 |
| 2017-02-20 | Bokslutskommuniké 2016 |
| 2016-11-30 | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | Kvartalsrapport 2016-Q2 |
| 2016-06-01 | Ordinarie utdelning RLS 0.00 SEK |
| 2016-05-31 | Kvartalsrapport 2016-Q1 |
| 2016-05-31 | Årsstämma 2016 |
| 2016-02-29 | Bokslutskommuniké 2015 |
| 2016-01-21 | Extra Bolagsstämma 2016 |
| 2015-11-30 | Kvartalsrapport 2015-Q3 |
| 2015-08-31 | Kvartalsrapport 2015-Q2 |
| 2015-06-12 | Ordinarie utdelning RLS 0.00 SEK |
| 2015-06-11 | Årsstämma 2015 |
| 2015-05-28 | Kvartalsrapport 2015-Q1 |
| 2015-02-27 | Bokslutskommuniké 2014 |
| 2014-11-28 | Kvartalsrapport 2014-Q3 |
| 2014-09-12 | Extra Bolagsstämma 2014 |
| 2014-08-29 | Kvartalsrapport 2014-Q2 |
| 2014-06-10 | Ordinarie utdelning RLS 0.00 SEK |
| 2014-06-09 | Årsstämma 2014 |
| 2014-05-23 | Kvartalsrapport 2014-Q1 |
| 2014-03-05 | Bokslutskommuniké 2013 |
| 2013-11-29 | Kvartalsrapport 2013-Q3 |
| 2013-09-04 | Kvartalsrapport 2013-Q2 |
| 2013-05-31 | Kvartalsrapport 2013-Q1 |
| 2013-05-08 | Split RLS 10:1 |
| 2013-04-11 | Ordinarie utdelning RLS 0.00 SEK |
| 2013-04-10 | Årsstämma 2013 |
| 2013-03-05 | Bokslutskommuniké 2012 |
| 2012-11-26 | Kvartalsrapport 2012-Q3 |
| 2012-08-31 | Kvartalsrapport 2012-Q2 |
| 2012-06-12 | Ordinarie utdelning RLS 0.00 SEK |
| 2012-06-11 | Årsstämma 2012 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2022-08-26 09:00:00
APRIL 1[st] - JUNE 30[th ](Previous year in brackets)
- Net sales amounted to TSEK 397 (TSEK 244).
- Earnings before interest and taxes (EBIT) amounted to MSEK -5,8 (MSEK 8,5).
- Earning per share before dilution at SEK -0,09 (SEK 0,13).
- Cash flow from operating activities amounted to TSEK -5 929 (TSEK -6 280).
- Liquid assets at the end of the period MSEK 5,8 (MSEK 6,9).
- Equity ratio was 43 % (87 %).
JANUARY 1[st] - JUNE 30[th ](Previous year in brackets)
- Net sales amounted to TSEK 705 (TSEK 302).
- Earnings before interest and taxes (EBIT) amounted to MSEK -11,1 (MSEK 2,2).
- Earning per share before dilution at SEK -0,16 (SEK 0,03).
- Cash flow from operating activities amounted to MSEK -12,7 (MSEK -12,1).
- Liquid assets at the end of the period MSEK 5,8 (MSEK 6,9).
- Equity ratio was 43 % (87 %).
SUMMARY OF EVENTS DURING SECOND QUARTER
- AGM was held on May 19.
- RLS signs distribution agreement for the Middle East with the aim of commercializing ChloraSolv.
- RLS introduces ChloraSolv for the animal segment in Scandinavia. Distribution agreements are signed with Swevet for Denmark, Norway and Sweden.
- ChloraSolv is approved for leg ulcers in Kuwait.
SUMMARY OF EVENTS AFTER SECOND QUARTER
- The Journal of Wound Care publishes case studies regarding ChloraSolv from three British clinics.
- Björn Larsson takes over as CEO of RLS Global as of October 1, 2022.
The Interim Report Q2, 2022, is enclosed and is also available here (https://rls.global/wp-content/uploads/2022/08/RLS_Global_Q2_2022_EN.pdf).
PUBLICATION
This information was submitted for publication through the agency of the below contact person, at 09.00 CET on August 26[th] 2022.
TRADING PLACE AND CERTIFIED ADVISER:
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17[th] May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. During the period 2012-2017, the company was listed on Aktietorget.
FOR MORE INFORMATION, PLEASE CONTACT:
Karin Fischer, CEO, RLS Global
E-mail: karin.fischer@rlsglobal.se
Tel: +46 702 48 46 51
Eva Jagenheim, CFO, RLS Global
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57